Page 2 - Roivant Sciences News Today

Former GOP presidential hopeful Vivek Ramaswamy had a successful career as an entrepreneur and is devoting some of his wealth to the struggling media outlet.

Former GOP presidential hopeful Vivek Ramaswamy is now BuzzFeed's fourth largest shareholder with a 7.7% stake in the company

- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis

Watch the full interview now as a VladTV Youtube Member: Click Here

Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Apr 29, 2024--

(Bloomberg) -- David Einhorn’s Greenlight Capital underperformed the “fundamentally broken” stock market at the start of the year, according to a letter to investors.Most Read from BloombergBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsTaylor Swift Is Proof That How We Critique Music Is BrokenZuckerberg Asks for Patience After Meta’s AI Push Irks InvestorsTech Giants Hit in Late Hours After Meta’s Outlook: Markets WrapFlorida&#...

“This historic shifting of capital is a beautiful opportunity set in which we can invest.”

In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023.

Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.53% from the company’s previous close. Other research analysts […]